The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The role of a soluble TNF receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial
Open accessAbstract
AIM: Tumour necrosis factor alpha (TNFalpha) is a cytokine recognised as a therapeutic target in chronic inflammatory diseases. METHODS: A randomised, double blind, placebo controlled parallel group trial is reported of etanercept (an IgG1-TNF p75 receptor fusion protein), administered once weekly for 12 weeks in 39 patients with severe corticosteroid refractory asthma. Efficacy was measured by change from the pretreatment baseline in Asthma Related Quality of Life (AQLQ) and Asthma Control (ACQ) Questionnaire scores (the primary endpoints), lung function, peak expiratory flow (PEF) and bronchial hyperresponsiveness (BHR). Sputum and serum inflammatory cells and cytokines, serum albumin and C reactive protein (CRP) as biomarkers of inflammation were also assessed. RESULTS: There was a small but significant difference in reduction of ACQ scores between treatment and placebo (-1.11 (95% CI -1.56 to -0.75) and -0.52 (95% CI -0.97 to -0.07), respectively, p = 0.037). There was no significant difference in improvements in AQLQ scores, lung function, PEF, BHR or exacerbation rates between the groups. Minor adverse events, including injection site pain and skin rashes, were more frequent with etanercept. There was a significant reduction in sputum macrophages and CRP, and increases in serum TNFalpha and albumin following treatment, but not in other laboratory parameters. CONCLUSION: Etanercept therapy over 12 weeks demonstrated only a small but significant improvement in asthma control and systemic inflammation, as measured by serum albumin and CRP. Larger randomised, placebo controlled trials are required to clarify the role of TNFalpha antagonism in subjects with severe refractory asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Su, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.024 · Cited by 212
Cited by
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlén, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1512oc · Cited by 460
Self-citationTargeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.003 · Cited by 375
Cascade of immune mechanism and consequences of inflammatory disorders
Megha, K., Joseph, X., Akhil, V., & Mohanan, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153712 · Cited by 355
Metadata
- Authors
- Morjaria, J. B., Chauhan, A. J., Babu, K. S., Polosa, R., Davies, D. E., & Holgate, S. T.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2008-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 584-591
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2172283099
- Cited by
- 190
- References
- 3
- FWCI
- 15.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of a soluble TNF receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. https://app.cochat.ai/papers/10.1136/thx.2007.086314
- The paper
- Morjaria, J. B., Chauhan, A. J., Babu, K. S., Polosa, R., Davies, D. E., & Holgate, S. T. (2008). The role of a soluble TNF receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. https://doi.org/10.1136/thx.2007.086314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.